ID   LC4-1
AC   CVCL_1374
SY   LC41
DR   BTO; BTO:0004945
DR   CLO; CLO_0009846
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03470796
DR   cancercelllines; CVCL_1374
DR   Cell_Model_Passport; SIDM00549
DR   ChEMBL-Cells; CHEMBL3308835
DR   ChEMBL-Targets; CHEMBL2366091
DR   Cosmic; 907787
DR   Cosmic; 996283
DR   Cosmic; 998692
DR   Cosmic; 1037719
DR   Cosmic-CLP; 907787
DR   DepMap; ACH-002267
DR   EGA; EGAS00001000978
DR   GDSC; 907787
DR   GEO; GSM827293
DR   GEO; GSM1670044
DR   GEO; GSM5137723
DR   GEO; GSM5137760
DR   IARC_TP53; 21471
DR   JCRB; JCRB0114
DR   LINCS_LDP; LCL-1037
DR   PharmacoDB; LC41_832_2019
DR   PRIDE; PXD023662
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1374
DR   PubChem_Cell_line; CVCL_1374
DR   Wikidata; Q54902172
RX   PubMed=3115091;
RX   PubMed=10233379;
RX   PubMed=10739008;
RX   PubMed=11226526;
RX   PubMed=14504097;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35124168;
RX   PubMed=35354797;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; Sanger).
CC   Sequence variation: Gene fusion; HGNC; 6997; MEF2D + HGNC; 17011; HNRNPUL1; Name(s)=MEF2D-HNRNPUL1 (PubMed=35354797).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=75.57%; East Asian, South=23.72%; South Asian=0.71%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Miscellaneous: STR profile from personal communication of Leo I.R.
CC   Misspelling: LC4-L1; PubMed=35124168.
ST   Source(s): Cosmic-CLP; JCRB; Direct_author_submission
ST   Amelogenin: X
ST   CSF1PO: 10,13
ST   D10S1248: 13
ST   D12S391: 18
ST   D13S317: 8,12
ST   D16S539: 9,10
ST   D18S51: 13,14
ST   D19S433: 12,14
ST   D1S1656: 15
ST   D21S11: 29,30
ST   D22S1045: 11,16
ST   D2S1338: 18,25
ST   D2S441: 13,14
ST   D3S1358: 14,15
ST   D5S818: 10,12
ST   D7S820: 8,10
ST   D8S1179: 13,14
ST   FGA: 23,25
ST   SE33: 17
ST   TH01: 7,9
ST   TPOX: 9,11
ST   vWA: 17,19
DI   NCIt; C9140; Childhood B acute lymphoblastic leukemia
DI   ORDO; Orphanet_99860; Precursor B-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   13Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 36
//
RX   PubMed=3115091; DOI=10.1002/ajh.2830260106;
RA   Yoshimura T., Mayumi M., Yorifuji T., Kim K.-M., Heike T.,
RA   Miyanomae T., Shinomiya K., Mikawa H.;
RT   "Establishment of a common acute lymphoblastic leukemia cell line
RT   (LC4-1) and effects of phorbol myristate acetate (PMA) on the surface
RT   antigen expression of the cell line.";
RL   Am. J. Hematol. 26:47-54(1987).
//
RX   PubMed=10233379; DOI=10.1111/j.1365-2141.1999.01284.x;
RA   Xu F., Taki T., Yang H.W., Hanada R., Hongo T., Ohnishi H.,
RA   Kobayashi M., Bessho F., Yanagisawa M., Hayashi Y.;
RT   "Tandem duplication of the FLT3 gene is found in acute lymphoblastic
RT   leukaemia as well as acute myeloid leukaemia but not in
RT   myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in
RT   children.";
RL   Br. J. Haematol. 105:155-162(1999).
//
RX   PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Frequent microsatellite instability and BAX mutations in T cell acute
RT   lymphoblastic leukemia cell lines.";
RL   Leuk. Res. 24:255-262(2000).
//
RX   PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Corrigendum to: Frequent microsatellite instability and BAX mutations
RT   in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24
RT   (2000),255-262.";
RL   Leuk. Res. 25:275-278(2001).
//
RX   PubMed=14504097; DOI=10.1182/blood-2003-02-0418;
RA   Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R.,
RA   Tsuchida M., Sugita K., Ida K., Hayashi Y.;
RT   "FLT3 mutations in the activation loop of tyrosine kinase domain are
RT   frequently found in infant ALL with MLL rearrangements and pediatric
RT   ALL with hyperdiploidy.";
RL   Blood 103:1085-1088(2004).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35124168; DOI=10.1016/j.jsbmb.2022.106068;
RA   Tamai M., Kasai S., Akahane K., Thu T.N., Kagami K., Komatsu C.,
RA   Abe M., Watanabe A., Goi K., Miyake K., Inaba T., Takita J., Goto H.,
RA   Minegishi M., Iwamoto S., Sugita K., Inukai T.;
RT   "Glucocorticoid receptor gene mutations confer glucocorticoid
RT   resistance in B-cell precursor acute lymphoblastic leukemia.";
RL   J. Steroid Biochem. Mol. Biol. 218:106068.1-106068.12(2022).
//
RX   PubMed=35354797; DOI=10.1038/s41467-022-29224-5;
RA   Leo I.R., Aswad L., Stahl M., Kunold E., Post F., Erkers T.,
RA   Struyf N., Mermelekas G., Joshi R.N., Gracia-Villacampa E.,
RA   Ostling P., Kallioniemi O.-P., Pokrovskaja Tamm K., Siavelis I.,
RA   Lehtio J., Vesterlund M., Jafari R.;
RT   "Integrative multi-omics and drug response profiling of childhood
RT   acute lymphoblastic leukemia cell lines.";
RL   Nat. Commun. 13:1691.1-1691.19(2022).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//